TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from MIRA Pharmaceuticals, Inc. ( (MIRA) ).
On October 15, 2025, MIRA Pharmaceuticals announced that its oral Mira-55 outperformed injected morphine in normalizing pain and reducing inflammation in a preclinical study. The study demonstrated that Mira-55 effectively restored pain thresholds and reduced inflammation through a direct CB2-receptor-mediated mechanism, offering a dual approach to treating chronic inflammatory pain. This supports the company’s plan to pursue an Investigational New Drug application, reinforcing its position in the non-opioid pain market.
More about MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing non-opioid pain management solutions. Their primary product is Mira-55, a non-psychotropic marijuana analog targeting the $70 billion non-opioid pain market.
Average Trading Volume: 594,914
Technical Sentiment Signal: Sell
For detailed information about MIRA stock, go to TipRanks’ Stock Analysis page.